Bolt Biotherapeutics (BOLT) Treasury Shares (2020 - 2025)

Bolt Biotherapeutics (BOLT) posted Treasury Shares of $249500.0 for Q4 2025, up 374.94% sequentially from $52533.0 in Q4 2023.

Bolt Biotherapeutics (BOLT) Treasury Shares (2020 - 2025) Analysis & Trends

Bolt Biotherapeutics has reported Treasury Shares for 5 years, with the latest figure at $249500.0 in Q4 2025.

Quarterly Treasury Shares changed N/A year-over-year to $249500.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $249500.0 (changed N/A YoY) and the FY2025 annual result came in at $249500.0, changed N/A from the prior year.
Treasury Shares climbed to $249500.0 in Q4 2025 per BOLT's latest filing, from $52533.0 in the prior quarter.
Over five years, Treasury Shares peaked at $336000.0 in Q4 2021 and troughed at $52533.0 in Q4 2023.
A 4-year average of $189975.0 and a median of $185683.5 in 2022 frame the typical range for Treasury Shares.
The sharpest annual moves came in 2021 and 2023: Treasury Shares slumped 97.79% in 2021, then sank 56.89% in 2023.
Over 4 years, Treasury Shares stood at $336000.0 in 2021, then sank by 63.73% to $121867.0 in 2022, then tumbled by 56.89% to $52533.0 in 2023, then soared by 374.94% to $249500.0 in 2025.
According to Business Quant data, Treasury Shares over the past three periods registered $249500.0, $52533.0, and $121867.0 for Q4 2025, Q4 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.24 Bn	131.39 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.01 Bn	78.02 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	65.61 Bn	60.42 Bn	1.37 Bn	-
4	Moderna	56.92 Bn	51.78 Bn	52.00 Mn	-
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.27 Bn	992.69 Mn	-
7	BioNTech SE	27.77 Bn	9.38 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn	-
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	2.72 Mn
10	Bolt Biotherapeutics	5.87 Mn	5.87 Mn	-	-

Download Data